[go: up one dir, main page]

MX2013004906A - Nuevos inhibidores especificos de la proteasa ns3 de hcv. - Google Patents

Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Info

Publication number
MX2013004906A
MX2013004906A MX2013004906A MX2013004906A MX2013004906A MX 2013004906 A MX2013004906 A MX 2013004906A MX 2013004906 A MX2013004906 A MX 2013004906A MX 2013004906 A MX2013004906 A MX 2013004906A MX 2013004906 A MX2013004906 A MX 2013004906A
Authority
MX
Mexico
Prior art keywords
protease inhibitors
novel specific
specific hcv
hcv
novel
Prior art date
Application number
MX2013004906A
Other languages
English (en)
Inventor
Philippe Halfon
Jerome Courcambeck
Mourad Bouzidi
Steven J Coats
Richard Anthony Whitaker
Original Assignee
Genoscience Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoscience Pharma filed Critical Genoscience Pharma
Publication of MX2013004906A publication Critical patent/MX2013004906A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se dirige a los compuestos, composiciones y métodos para tratar o prevenir las infecciones virales, particularmente, el HCV, en los pacientes humanos o en otros anfitriones animales.
MX2013004906A 2010-11-01 2011-10-28 Nuevos inhibidores especificos de la proteasa ns3 de hcv. MX2013004906A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40898910P 2010-11-01 2010-11-01
PCT/US2011/058404 WO2012061248A2 (en) 2010-11-01 2011-10-28 Novel specific hcv ns3 protease inhibitors

Publications (1)

Publication Number Publication Date
MX2013004906A true MX2013004906A (es) 2013-12-06

Family

ID=46025037

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004906A MX2013004906A (es) 2010-11-01 2011-10-28 Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Country Status (10)

Country Link
US (1) US8729014B2 (es)
EP (1) EP2635570B1 (es)
JP (1) JP5828903B2 (es)
CN (1) CN103328466B (es)
AU (1) AU2011323658A1 (es)
BR (1) BR112013010836A2 (es)
CA (1) CA2815855C (es)
IL (1) IL225908A0 (es)
MX (1) MX2013004906A (es)
WO (1) WO2012061248A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012MN02896A (es) 2010-06-24 2015-06-12 Panmed Ltd
EP2635570B1 (en) 2010-11-01 2017-12-13 RFS Pharma, LLC. Novel specific hcv ns3 protease inhibitors
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
CA2858814A1 (en) 2012-01-12 2013-07-18 Rfs Pharma, Llc Hcv ns3 protease inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
JP2017513852A (ja) * 2014-04-15 2017-06-01 コクリスタル ファーマ，インコーポレイテッド Ｃ型肝炎ウイルスの強力及び選択的な阻害剤
CN105315261A (zh) * 2014-08-04 2016-02-10 正大天晴药业集团股份有限公司 Hcv ns3蛋白酶抑制剂的钠盐

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000536A1 (en) 1993-06-22 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
EP1268519B1 (en) 2000-04-03 2005-06-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
JP2005504043A (ja) 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
ES2361011T3 (es) 2002-05-20 2011-06-13 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c.
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
KR20070007759A (ko) 2003-07-10 2007-01-16 아칠리온 파르마세우티칼스 인코포레이티드 바이러스 복제 억제제로서 유용한 치환된 아릴티오우레아유도체
EP1713822B1 (en) 2004-01-30 2010-03-17 Medivir AB Hcv ns-3 serine protease inhibitors
US7399749B2 (en) 2004-05-20 2008-07-15 Schering Corporation Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN100486397C (zh) 2005-04-19 2009-05-06 皇家飞利浦电子股份有限公司 包括红色发射陶瓷发光转换器的照明系统
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
RU2008107972A (ru) 2005-08-01 2009-09-10 Мерк энд Ко., Инк. (US) Макроциклические пептиды в качестве ингибиторов ns3-протеазы hcv
WO2007089618A2 (en) 2006-01-27 2007-08-09 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
CN101495457A (zh) * 2006-07-05 2009-07-29 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
KR101053814B1 (ko) 2006-11-24 2011-08-03 가부시키가이샤 시마쓰세사쿠쇼 Ｘ선 투시 촬영 장치
US20080287449A1 (en) 2007-04-26 2008-11-20 Deqiang Niu Aza-tripeptide hepatitis c serine protease inhibitors
MX2010006210A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hcv de tripeptido fluorado.
EP2237666A4 (en) 2007-12-21 2012-05-16 Avila Therapeutics Inc HCV PROTEASE INHIBITORS AND USES THEREOF
US8293705B2 (en) * 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
BRPI0911260A2 (pt) 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
CN102140100B (zh) 2010-01-27 2014-06-11 爱博新药研发(上海)有限公司 高效抑制丙型肝炎病毒的多环化合物及其制备方法和用途
EP2635570B1 (en) 2010-11-01 2017-12-13 RFS Pharma, LLC. Novel specific hcv ns3 protease inhibitors

Also Published As

Publication number Publication date
AU2011323658A1 (en) 2013-05-23
WO2012061248A3 (en) 2012-08-02
US8729014B2 (en) 2014-05-20
EP2635570A4 (en) 2014-04-16
JP2013542955A (ja) 2013-11-28
EP2635570B1 (en) 2017-12-13
EP2635570A2 (en) 2013-09-11
CA2815855C (en) 2016-02-02
BR112013010836A2 (pt) 2019-09-24
US20120129765A1 (en) 2012-05-24
CA2815855A1 (en) 2012-05-10
JP5828903B2 (ja) 2015-12-09
WO2012061248A2 (en) 2012-05-10
WO2012061248A8 (en) 2013-08-01
IL225908A0 (en) 2013-06-27
CN103328466B (zh) 2016-08-03
CN103328466A (zh) 2013-09-25

Similar Documents

Publication Publication Date Title
WO2013106689A8 (en) Hcv ns3 protease inhibitors
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2013001579A (es) Inhibidores del virus de la hepatitis c
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
SG179566A1 (en) Hcv protease inhibitors
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
PH12013501543A1 (en) Hepatitis c virus inhibitors
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
ES2572329A2 (es) Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para uso en el tratamientodel vhc
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
WO2012083048A3 (en) Anti-viral compounds
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
WO2012083053A3 (en) Anti-viral compounds
IN2014CN03113A (es)
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
PL2209789T3 (pl) Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV

Legal Events

Date Code Title Description
FG Grant or registration